FILE PHOTO: Logos of Pfizer at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov/File Photo

Pfizer licensed three preclinical CAR-T therapies from China's Starna Therapeutics in a deal worth up to $2.6 billion on Wednesday afternoon. The agreement includes $330 million in upfront cash, with the remainder tied to regulatory and sales milestones.